These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 22593575)

  • 41. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.
    Persson L; Gälman C; Angelin B; Rudling M
    Endocrinology; 2009 Mar; 150(3):1140-6. PubMed ID: 19008317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
    Le May C; Berger JM; Lespine A; Pillot B; Prieur X; Letessier E; Hussain MM; Collet X; Cariou B; Costet P
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1484-93. PubMed ID: 23559630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
    Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
    Seidah NG; Poirier S; Denis M; Parker R; Miao B; Mapelli C; Prat A; Wassef H; Davignon J; Hajjar KA; Mayer G
    PLoS One; 2012; 7(7):e41865. PubMed ID: 22848640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
    Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
    Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H; Samarghandi A; Zhang N; Yao Z; Xiong M; Teng BB
    Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
    Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
    J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
    Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.
    Hussain Y; Ding Q; Connelly PW; Brunt JH; Ban MR; McIntyre AD; Huff MW; Gros R; Hegele RA; Feldman RD
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):213-21. PubMed ID: 25395619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
    Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.